Neoadjuvant Nivolumab Therapy for Esophageal Squamous Cell Carcinoma: A Single-Arm, Phase II Study
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose Programmed death-1/programmed death-ligand 1 (PD-L1) inhibitors have shown efficacy in metastatic esophageal squamous cell carcinoma (ESCC) therapy. However, data is still limited regarding neoadjuvant immunotherapy for operable ESCC. Materials and Methods Patients with clinical stage T2 or T3 and N0 ESCC received three cycles of nivolumab therapy every two weeks before surgical resection. The primary endpoint is major pathologic responses (MPR) rate (≤ 10% of residual viable tumor [RVT]). Results Total 20 patients completed the planned nivolumab therapy. Among them, 17 patients underwent surgery as protocol, showing MPR in two patients (MPR rate, 11.8%), including one pathologic complete response, on conventional pathologic response evaluation. Pathologic response was re-evaluated using the immune-related pathologic response criteria based on immune-related RVT (irRVT). Three patients were classified as immunologic major pathologic response (iMPR; ≤ 10% irRVT, iMPR rate: 17.6%), five as pathologic partial response (> 10% and < 90% irRVT), and nine as pathologic nonresponse (≥ 90% irRVT). The combined positive score (CPS) for PD-L1 in the baseline samples was predictable for iMPR, with the probability as 37.5% in CPS ≥ 10 (3/8) and 0% in CPS < 10 (0/9). Conclusion Although the efficacy of neoadjuvant nivolumab therapy was modest in unselected ESCC patients, further researches on neoadjuvant immunotherapy are necessary in patients with PD-L1 expressed ESCC.
Abstract
Purpose Programmed death-1/programmed death-ligand 1 (PD-L1) inhibitors have shown efficacy in metastatic esophageal squamous cell carcinoma (ESCC) therapy. However, data is still limited regarding neoadjuvant immunotherapy for operable ESCC. Materials and Methods Patients with clinical stage T2 or T3 and N0 ESCC received three cycles of nivolumab therapy every two weeks before surgical resection. The primary endpoint is major pathologic responses (MPR) rate (≤ 10% of residual viable tumor [RVT]). Results Total 20 patients completed the planned nivolumab therapy. Among them, 17 patients underwent surgery as protocol, showing MPR in two patients (MPR rate, 11.8%), including one pathologic complete response, on conventional pathologic response evaluation. Pathologic response was re-evaluated using the immune-related pathologic response criteria based on immune-related RVT (irRVT). Three patients were classified as immunologic major pathologic response (iMPR; ≤ 10% irRVT, iMPR rate: 17.6%), five as pathologic partial response (> 10% and < 90% irRVT), and nine as pathologic nonresponse (≥ 90% irRVT). The combined positive score (CPS) for PD-L1 in the baseline samples was predictable for iMPR, with the probability as 37.5% in CPS ≥ 10 (3/8) and 0% in CPS < 10 (0/9). Conclusion Although the efficacy of neoadjuvant nivolumab therapy was modest in unselected ESCC patients, further researches on neoadjuvant immunotherapy are necessary in patients with PD-L1 expressed ESCC.
참고문헌 (33)
- Sung H, "Global cancer statistics 2020 : GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries", CA Cancer J Clin, 71, pp.209~249 (2021)
- Medical Research Council Oesophageal Cancer Working Group, "Surgical resection with or without preoperative chemotherapy in oesophageal cancer : a randomised controlled trial", Lancet, 359, pp.1727~1733 (2002)
- Ando N, "A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus(JCOG9907)", Ann Surg Oncol, 19, pp.68~74 (2012)
- Yang H, "Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus(NEOCRTEC5010) : a phase III multicenter, randomized, open-label clinical trial", J Clin Oncol, 36, pp.2796~2803 (2018)
- Shapiro J, "Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer(CROSS) : long-term results of a randomised controlled trial", Lancet Oncol, 16, pp.1090~1098 (2015)
- Mariette C, "Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer : final analysis of randomized controlled phase III trial FFCD 9901", J Clin Oncol, 32, pp.2416~2422 (2014)
- Donohoe CL, "Neoadjuvant treatment of locally advanced esophageal and junctional cancer : the evidence-base, current key questions and clinical trials", J Thorac Dis, 9, pp.S697~S704 (2017)
- Kato K, "Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy(ATTRACTION-3) : a multicentre, randomised, open-label, phase 3 trial", Lancet Oncol, 20, pp.1506~1517 (2019)
- Kojima T, "Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer", J Clin Oncol, 38, pp.4138~4148 (2020)
- Shen L, "Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma(RATIONALE-302) : a randomized phase III study", J Clin Oncol, 40, pp.3065~3076 (2022)
- Kelly RJ, "Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer", N Engl J Med, 384, pp.1191~1203 (2021)
- Sun JM, "Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer(KEYNOTE-590) : a randomised, placebo-controlled, phase 3 study", Lancet, 398, pp.759~771 (2021)
- Doki Y, "Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma", N Engl J Med, 386, pp.449~462 (2022)
- Chirieac LR, "Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation", Cancer, 103, pp.1347~1355 (2005)
- Cottrell TR, "Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma : a proposal for quantitative immune-related pathologic res-ponse criteria(irPRC)", Ann Oncol, 29, pp.1853~1860 (2018)
- Lee J, "Nivolumab for esophageal squamous cell carcinoma and the predictive role of PD-L1 or CD8 expression in its therapeutic effect", Cancer Immunol Immunother, 70, pp.1203~1211 (2021)
- Cho J, "CD47 overexpression is common in intestinal non-GCB type diffuse large B-cell lymphoma and associated with 18q21 gain", Blood Adv, 6, pp.6120~6130 (2022)
- Aung TN, "A new tool for technical standardization of the Ki67immunohistochemical assay", Mod Pathol, 34, pp.1261~1270 (2021)
- Eisenhauer EA, "New response evaluation criteria in solid tumours : revised RECIST guideline(version 1. 1)", Eur J Cancer, 45, pp.228~247 (2009)
- -fluorodeoxyglucose and positron emission tomography : review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer(EORTC)PET Study Group, "Eur J Cancer", 1999, 1773~1782
- Park S, "Adju-vant durvalumab for esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy : a placebo-controlled, randomized, double-blind, phase II study", ESMO Open, 7, pp.100385~ (2022)
- Park S, "Durvalumab and tremelimumab with definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma", Cancer, 128, pp.2148~2158 (2022)
- Hellmann MD, "Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers : proposal for the use of major pathological response as a surrogate endpoint", Lancet Oncol, 15, pp.e42~e50 (2014)
- Cloyd JM, "Association of clinical factors with a major pathologic response following preoperative therapy for pancreatic ductal adenocarcinoma", JAMA Surg, 152, pp.1048~1056 (2017)
- Yang W, "Neoadjuvant programmed cell death 1 blockade combined with chemotherapy for resectable esophageal squamous cell carcinoma", J Immunother Cancer, 10, pp.e003497~ (2022)
- Forde PM, "Neoadjuvant PD-1 blockade in resectable lung cancer", N Engl J Med, 378, pp.1976~1986 (2018)
- Bando H, "TENERGY : multicenter phase II study of atezolizumab monotherapy following definitive chemoradiotherapy with 5-FU plus cisplatin in patients with unresectable locally advanced esophageal squamous cell carcinoma", BMC Cancer, 20, pp.336~ (2020)
- Dieu-Nosjean MC, "Tertiary lymphoid structures, drivers of the anti-tumor responses in human cancers", Immunol Rev, 271, pp.260~275 (2016)
- Japan Esophageal Society, "Japanese Classification of Esophageal Cancer, 11th Edition : part II and III", Esophagus, 14, pp.37~65 (2017)
- Im HJ, "Current methods to define metabolic tumor volume in positron emission tomography : which one is better?", Nucl Med Mol Imaging, 52, pp.5~15 (2018)
- Crabtree TD, "Evaluation of the reliability of clinical staging of T2 N0 esophageal cancer : a review of the Society of Thoracic Surgeons database", Ann Thorac Surg, 96, pp.382~390 (2013)
- Li Q, "Neoadjuvant immunotherapy for resectable esophageal cancer : a review", Front Immunol, 13, pp.1051841~ (2022)
- Liu J, "Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma", J Immunother Cancer, 10, pp.e004291~ (2022)